| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5894d694d4a784d601f503d79e518f2d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate |
2019-03-06^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bf66c13d4a758b51bac9be2ff4c2224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23704b301ed2640497beedd79c10633a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8204c8400b71900f0237834ef5e3d75b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b9c97b1c87e6e15ec33e24c29ae524d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a86f969571893e7d4a5a13cbd37a056f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fff3abd575dc7c0df356a956ee3d38c3 |
| publicationDate |
2019-09-26^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019292273-A1 |
| titleOfInvention |
Methods for reducing cardiovascular risk |
| abstract |
The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11395669-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11517340-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11439418-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11406416-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020085444-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11737771-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11529157-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11717308-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11712231-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11712256-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11730501-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11673967-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11246612-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10842498-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115413625-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253278-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11547427-B2 |
| priorityDate |
2018-03-06^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |